SEC Info - Augmedix, Inc. - ‘8-K’ for 9/12/22

SEC Info℠

Home

Help

Please Sign In

Augmedix, Inc. – ‘8-K’ for 9/12/22

On: Monday, 9/12/22, at 7:24pm ET · As of: 9/13/22 · For: 9/12/22 · Accession #: 1213900-22-55389 · File #: 1-40890

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/13/22  Augmedix, Inc.                    8-K:7,9     9/12/22   11:4.6M                                   EdgarAgents LLC/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 2: EX-99.1     Augmedix Investor Presentation September 2022       HTML     24K 
 6: R1          Cover                                               HTML     49K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- ea165687-8k_augmedix_htm            XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- augx-20220912_lab                     XML     96K 
 5: EX-101.PRE  XBRL Presentations -- augx-20220912_pre              XML     64K 
 3: EX-101.SCH  XBRL Schema -- augx-20220912                         XSD     13K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
11: ZIP         XBRL Zipped Folder -- 0001213900-22-055389-xbrl      Zip     23K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0001769804 i false 0001769804 2022-09-12 2022-09-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): i September 12, 2022

i AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

i Delaware

i 000-56036

i 83-3299164

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

i 111 Sutter Street, i Suite 1300, i San Francisco, i California i 94104

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: ( i 888) i 669-4885

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common Stock, $0.0001 par value per share		i AUGX		The i Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐

Item 7.01. Regulation FD Disclosure.

On September 12, 2022, a presentation entitled “Augmedix Investor Presentation September 2022” was made available on the Presentations page of the Company’s website at https://ir.augmedix.com/company-information/presentations. The presentation is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Augmedix Investor Presentation September 2022.

104		Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

C: 1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AUGMEDIX, INC.

Dated: September 13, 2022	By:	/s/ *Paul Ginocchio*
		Paul Ginocchio
		Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed as of:	9/13/22	None on these Dates
Filed on / For Period end:	9/12/22
		List all Filings

↑Top

Filing Submission 0001213900-22-055389 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)